Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Identification of Novel Targets for Antibody or Chimeric Antigen Receptor (CAR) Based Immunotherapy in AML: Characterizing the Surfaceome from Primary Patient Samples

Thomas Koehnke, MD, Liu Xilong, Sascha Haubner, MD, Christina Krupka, PhD, Victor Solis-Mezarino, Franz Herzog, PhD, Wolfgang Hiddemann, MD PhD, Marion S. Subklewe, MD

Blood (2017) 130 (Supplement 1): 3968.

https://doi.org/10.1182/blood.V130.Suppl_1.3968.3968

Published: 2017

Journal Articles

Minimal Residual Disease (MRD) Detection By Flow Cytometry during Aplasia and Post-Induction Is an Independent Prognostic Parameter for Relapse-Free Survival in AML

Veit Bücklein, MD, Thomas Koehnke, MD, Sandra Rechkemmer, Frauke Schnorfeil, PhD, Stephanie Schneider, PhD, Maja Rothenberg-Thurley, PhD, Klaus H. Metzeler, MD, Cristina Sauerland, Wolfgang Hiddemann, MD PhD, Karsten Spiekermann, Marion S. Subklewe, MD

Blood (2017) 130 (Supplement 1): 5081.

https://doi.org/10.1182/blood.V130.Suppl_1.5081.5081

Published: 2017

Journal Articles

Tyrosin Kinase Inhibition Restores the Membrane Localization of FLT3-ITD

Katrin S. Reiter, Harald Polzer, PhD, Christina Krupka, Binje Vick, PhD, Andreas Maiser, Marion S. Subklewe, MD, Irmela Jeremias, MD, Heinrich Leonhardt, PhD, Karsten Spiekermann, MD, Philipp A. Greif, MD

Blood (2015) 126 (23): 1274.

https://doi.org/10.1182/blood.V126.23.1274.1274

Published: 2015

Journal Articles

DNMT3A Mutations Associate with Shorter Survival and Modulate the Prognostic Impact of Mutated NPM1: an Analysis Based on Comprehensive Mutational Screening of 660 AML Patients Treated on German AML Cooperative Group (AMLCG) Trials

Blood (2015) 126 (23): 3815.

https://doi.org/10.1182/blood.V126.23.3815.3815

Published: 2015

Journal Articles

Identifying Immune Resistance Mechanisms to CD33/CD3 BiTE® Antibody Construct (AMG 330) Mediated Cytotoxicity

Christina Krupka, Thomas Köhnke, MD, Peter Kufer, Roman Kischel, Felix S. Lichtenegger, Franziska Brauneck, Stefan Rohling, Torben Altmann, Wolfgang Hiddemann, MD PhD, Marion S. Subklewe, MD

Blood (2015) 126 (23): 3677.

https://doi.org/10.1182/blood.V126.23.3677.3677

Published: 2015

Journal Articles

Next-Generation Dendritic Cell Vaccination in Postremission Therapy of AML: Results of a Clinical Phase I Trial

Katrin Deiser, Felix S. Lichtenegger, Frauke Schnorfeil, Thomas Koehnke, Torben Altmann, Veit Buecklein, Andreas Moosmann, Monika Brueggemann, Beate Wagner, Wolfgang Hiddemann, Iris Bigalke, Gunnar Kvalheim, Marion S. Subklewe, MD

Blood (2015) 126 (23): 3805.

https://doi.org/10.1182/blood.V126.23.3805.3805

Published: 2015

Journal Articles

Targeted, Deep Sequencing of Adult AML Patients Treated on the AMLCG-2008 Trial Detects Clonal Heterogeneity in 52% of Patients at Initial Diagnosis and Reveals Patterns of Clonal Evolution

Maja Rothenberg-Thurley, PhD, Stephanie Schneider, Dr. rer. nat., Tobias Herold, MD, Nikola P Konstandin, Annika Dufour, PhD, Kathrin Bräundl, Bianka Ksienzyk, Evelyn Zellmeier, Philipp A Greif, MD, Michael Fiegl, MD, Marion S. Subklewe, MD, Stefan K Bohlander, MD, Wolfgang Hiddemann, MD, Jan Braess, MD, Karsten Spiekermann, MD, Klaus H. Metzeler, MD

Blood (2014) 124 (21): 697.

https://doi.org/10.1182/blood.V124.21.697.697

Published: 2014

Journal Articles

Analysis of Cooperating Genetic Events in MLLT3-MLL Rearranged Acute Myeloid Leukemia (AML) by Targeted Next-Generation Sequencing of 16 Leukemia-Related Genes Reveals Frequent Mutations Affecting Growth Factor Signalling Pathways and Provides Evidence for Clonal Heterogeneity

Klaus H. Metzeler, MD, Nadine Sandhöfer, Tanja Hinrichsen, Evelyn Zellmeier, Bianka Ksienzyk, Annika Dufour, PhD, Stephanie Schneider, PhD, Purvi M. Kakadia, PhD, Philipp A Greif, MD, Marion S. Subklewe, MD, Stefan K Bohlander, MD, Hanns-Georg Klein, MD, Wolfgang Hiddemann, MD, Karsten Spiekermann, MD

Blood (2012) 120 (21): 1379.

https://doi.org/10.1182/blood.V120.21.1379.1379

Published: 2012

NARROW

Identification of Novel Targets for Antibody or Chimeric Antigen Receptor (CAR) Based Immunotherapy in AML: Characterizing the Surfaceome from Primary Patient Samples

Minimal Residual Disease (MRD) Detection By Flow Cytometry during Aplasia and Post-Induction Is an Independent Prognostic Parameter for Relapse-Free Survival in AML

Tyrosin Kinase Inhibition Restores the Membrane Localization of FLT3-ITD

DNMT3A Mutations Associate with Shorter Survival and Modulate the Prognostic Impact of Mutated NPM1: an Analysis Based on Comprehensive Mutational Screening of 660 AML Patients Treated on German AML Cooperative Group (AMLCG) Trials

Identifying Immune Resistance Mechanisms to CD33/CD3 BiTE® Antibody Construct (AMG 330) Mediated Cytotoxicity

Next-Generation Dendritic Cell Vaccination in Postremission Therapy of AML: Results of a Clinical Phase I Trial

Targeted, Deep Sequencing of Adult AML Patients Treated on the AMLCG-2008 Trial Detects Clonal Heterogeneity in 52% of Patients at Initial Diagnosis and Reveals Patterns of Clonal Evolution

Analysis of Cooperating Genetic Events in MLLT3-MLL Rearranged Acute Myeloid Leukemia (AML) by Targeted Next-Generation Sequencing of 16 Leukemia-Related Genes Reveals Frequent Mutations Affecting Growth Factor Signalling Pathways and Provides Evidence for Clonal Heterogeneity

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only